Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib/II Study to Evaluate Efficacy, Safety and Tolerability of KN046 Monotherapy or in Combination With Nab-paclitaxel in Subjects With Triple-negative Breast Cancer

Trial Profile

A Phase Ib/II Study to Evaluate Efficacy, Safety and Tolerability of KN046 Monotherapy or in Combination With Nab-paclitaxel in Subjects With Triple-negative Breast Cancer

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 12 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Erfonrilimab (Primary) ; Paclitaxel (Primary)
  • Indications Advanced breast cancer; Male breast cancer; Triple negative breast cancer
  • Focus Therapeutic Use
  • Sponsors Jiangsu Alphamab Biopharmaceuticals

Most Recent Events

  • 07 Jun 2023 Status changed from active, no longer recruiting to completed.
  • 10 Dec 2022 Results(As of May 9, 2022; n=27 ) assessing Efficacy, Safety, and Tolerability of KN046 in combination with Nab-paclitaxel in Metastatic Triple-negative Breast Cancer presented at the 45th Annual San Antonio Breast Cancer Symposium
  • 16 Nov 2021 Planned End Date changed from 15 Sep 2021 to 15 Sep 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top